Review
Pharmacology & Pharmacy
Zvonimir Petric, Joao Goncalves, Paulo Paixao
Summary: Monoclonal antibodies have revolutionized the treatment of chronic inflammatory diseases, but they face challenges related to their immunogenicity, effectiveness, and safety. Biosimilars have emerged as a cost-effective alternative and have been shown to be as safe and effective as the originator drugs in treating IBD patients.
Article
Biotechnology & Applied Microbiology
Yuan Shi, Wei He, Ming Zhong, Minhao Yu
Summary: IFX/ADA and VDZ are widely used biologics for inflammatory bowel diseases, and the GIMATS module showed the best performance in predicting patient responses, dividing them into metabolic, immune, and normal types. A simplified 6-gene model called MIN score was established as a substitute for GIMATS module to assist with IFX/ADA and VDZ selection based on patient classification.
Article
Gastroenterology & Hepatology
Haggai Bar-Yoseph, Alexandra Blatt, Shiran Gerassy, Sigal Pressman, Amjad Mousa, Edmond Sabo, Matti Waterman, Bella Ungar, Shomron Ben-Horin, Yehuda Chowers
Summary: Therapeutic drug monitoring is essential when guiding anti-TNF therapy for inflammatory bowel disease. This study found differences in tissue dynamics between infliximab and adalimumab, with SDL correlating with tissue free drug levels. Understanding these interactions could lead to improved therapeutic strategies in the future.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Medicine, General & Internal
Anna Pekala, Rafal Filip, David Aebisher
Summary: This study aimed to determine the frequency of ADA in IBD patients during therapy with CT-P13, finding ADA in 50% of patients with undetectable levels of the drug. The analysis showed no relationship between response to treatment and antibody titers, but a significant relationship between undetectable levels of CT-P13 and the presence of ADA at week 6 of therapy was found. Patients with undetectable levels of CT-P13 before the third induction dose were at high risk of anti-drug antibodies and primary non-response.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Pharmacology & Pharmacy
C. Erdogan, M. B. Durak, A. Alkan, V. Kilic, F. Kivrakoglu, K. Kosar, I. Yuksel
Summary: This study evaluated the long-term clinical effectiveness and safety of infliximab (IFX) and adalimumab (ADA) in Crohn's disease patients who had not previously received a biologic treatment. The results showed no significant differences in the long-term effectiveness and safety of IFX and ADA in biologic-naive patients with CD.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2023)
Review
Pediatrics
So Yoon Choi, Ben Kang
Summary: The introduction of biological agents, particularly anti-TNF agents, has significantly improved the long-term prognosis of patients with inflammatory bowel disease (IBD). In pediatric populations, only two biological agents, infliximab (IFX) and adalimumab (ADL), have been approved for use. ADL has shown efficacy in achieving mucosal healing (MH) and histological remission in both naive patients and those who have previously received biologic treatment. Therapeutic drug monitoring may further enhance the effectiveness of ADL treatment and reduce treatment failure.
FRONTIERS IN PEDIATRICS
(2022)
Article
Gastroenterology & Hepatology
Rachel Levy, Manar Matar, Maya Zvuloni, Raanan Shamir, Amit Assa
Summary: TC response to adjustment of anti-TNFa treatment can be predicted for adalimumab but not for infliximab. Decreasing interval for adalimumab results in increased TC, while increasing interval for adalimumab and dose increase for infliximab both lead to decreased TC.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2023)
Review
Obstetrics & Gynecology
Han Wang, Yue Hu, Fang Chen, Mengdie Shen
Summary: This study aimed to evaluate the risk of adverse pregnancy outcomes following treatment with infliximab and adalimumab in women with IBD. The results showed that there was no difference in the risk of adverse pregnancy outcomes between infliximab and adalimumab therapy in women with IBD.
BMC PREGNANCY AND CHILDBIRTH
(2022)
Article
Gastroenterology & Hepatology
Alejandro Llanos-Chea, Jason M. Shapiro, Rachel W. Winter, Logan Jerger, Timothy Menz, Meghan Gibson, Alison M. Friedmann, Diana Treaba, Konstantinos Papamichael, Adam S. Cheifetz, Sonia Friedman, Matthew J. Hamilton, Harland S. Winter
Summary: This study reported a case series of young IBD patients who were treated with IFX monotherapy and developed lymphoma, with three of the patients having bone involvement. Further research may be needed to determine the true lymphoma risk in patients treated with IFX monotherapy.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Biochemistry & Molecular Biology
Giammarco Mocci, Giorgia Bodini, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefania Chiri, Giovanni Aragona, Patrizia Perazzo, Antonio Ferronato, Maria Giovanna Graziani, Cristiano Pagnini, Costantino Zampaletta, Camilla Graziosi, Marcello Picchio, Walter Elisei, Giovanni Maconi, Antonio Tursi
Summary: This study compared the efficacy and safety of GP2017 and its originator in IBD patients in a real-life setting, and the results showed that both GP2017 and its originator were equally effective and safe for the treatment of IBD.
Review
Immunology
Philip J. Smith, Mathurin Fumery, Rupert W. Leong, Kerri Novak, Axel Dignass
Summary: This article provides an overview of the clinical trial and real-world data for the subcutaneous formulation of infliximab (IFX SC) for the treatment of inflammatory bowel disease (IBD). It highlights the potential benefits of switching from intravenous (IV) to SC administration and discusses therapeutic drug monitoring and patient perspectives. The evidence suggests that IFX SC is well tolerated and effective in patients with stable disease.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2023)
Article
Gastroenterology & Hepatology
Alexa N. Sasson, Ashwin N. Ananthakrishnan
Summary: This study suggests that patients with high titers of anti-drug antibodies to infliximab are as likely to respond to adalimumab therapy as those with low titers, indicating that high titers of antibodies are not predictive of treatment failure.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Maria Cappello, Anita Busacca, Walter Fries, Anna Viola, Giuseppe Costantino, Antonio Magnano, Elisa Vinci, Concetta Ferracane, Antonino Carlo Privitera, Giovita Piccillo, Nunzio Belluardo, Emiliano Giangreco, Claudio Romano, Michele Citrano, Francesco Graziano, Serena Garufi, Carmelo Bertolami, Marco Ventimiglia, Barbara Scrivo, Giulia Teresi, Sara Renna, Giulia Rizzuto, Angelo Casa, Ambrogio Orlando
Summary: This study aimed to evaluate the safety and effectiveness of ADA biosimilar ABP 501 in patients with inflammatory bowel disease. The results showed that the safety and effectiveness of ABP 501 were overall similar to those of the ADA originator, indicating that switching from the originator to ABP 501 was safe and effective.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Medicine, General & Internal
Marta Vernero, Cristina Bezzio, Davide G. Ribaldone, Stefania Costa, Davide Scalvini, Elisa Tribocco, Gianpiero Manes, Simone Saibeni
Summary: This study evaluated the effectiveness and safety of GP2017, a biosimilar drug, in the treatment of inflammatory bowel disease (IBD). The results showed that GP2017 is an effective and safe therapy for IBD patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, Research & Experimental
Ran Jin, Chidozie Nduka, Delphine Courmier, Hannah Knight, Rachael Meadows, James Piercy, J. R. F. Cummings, Waldemar Radziszewski
Summary: The use of ABP 501 biosimilar in the treatment of inflammatory bowel disease has shown positive outcomes and high satisfaction among patients.
ADVANCES IN THERAPY
(2023)
Article
Gastroenterology & Hepatology
Shiran Gerassy-Vainberg, Alexandra Blatt, Yael Danin-Poleg, Katya Gershovich, Edmond Sabo, Alex Nevelsky, Shahar Daniel, Aviva Dahan, Oren Ziv, Rishu Dheer, Maria T. Abreu, Omry Koren, Yechezkel Kashi, Yehuda Chowers
Article
Gastroenterology & Hepatology
Oriana M. Damas, Derek Estes, Danny Avalos, Maria A. Quintero, Diana Morillo, Francia Caraballo, Johanna Lopez, Amar R. Deshpande, David Kerman, Jacob L. McCauley, Ana Palacio, Maria T. Abreu, Seth J. Schwartz
DIGESTIVE DISEASES AND SCIENCES
(2018)
Article
Gastroenterology & Hepatology
Andres J. Yarur, Anjali Jain, Maria A. Quintero, Frank Czul, Amar R. Deshpande, David H. Kerman, Maria T. Abreu
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2019)
Article
Immunology
Jason Miska, Jen Bon Lui, Kevin H. Toomer, Priyadharshini Devarajan, Xiaodong Cai, JeanMarie Houghton, Diana M. Lopez, Maria T. Abreu, Gaofeng Wang, Zhibin Chen
JOURNAL OF EXPERIMENTAL MEDICINE
(2018)
Article
Multidisciplinary Sciences
Juan F. Burgueno, Jessica K. Lang, Ana M. Santander, Irina Fernandez, Ester Fernandez, Julia Zaias, Maria T. Abreu
Article
Multidisciplinary Sciences
Li Zhang, Jingjing Meng, Yuguang Ban, Richa Jalodia, Irina Chupikova, Irina Fernandez, Nivis Brito, Umakant Sharma, Maria T. Abreu, Sundaram Ramakrishnan, Sabita Roy
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2019)
Article
Medicine, General & Internal
B. E. Sands, W. J. Sandborn, R. Panaccione, C. D. O'Brien, H. Zhang, J. Johanns, O. J. Adedokun, K. Li, L. Peyrin-Biroulet, G. Van Assche, S. Danese, S. Targan, M. T. Abreu, T. Hisamatsu, P. Szapary, C. Marano
NEW ENGLAND JOURNAL OF MEDICINE
(2019)
Editorial Material
Gastroenterology & Hepatology
Maria T. Abreu
DIGESTIVE DISEASES AND SCIENCES
(2019)
Editorial Material
Gastroenterology & Hepatology
Maria T. Abreu
DIGESTIVE DISEASES AND SCIENCES
(2019)
Editorial Material
Gastroenterology & Hepatology
Julia Fritsch, Maria T. Abreu
Review
Gastroenterology & Hepatology
Juan F. Burgueno, Maria T. Abreu
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
(2020)
Editorial Material
Gastroenterology & Hepatology
Maria T. Abreu, William J. Sandborn
Editorial Material
Gastroenterology & Hepatology
Marla C. Dubinsky, Rory Collins, Maria T. Abreu
Article
Gastroenterology & Hepatology
Maria T. Abreu, Julie M. Davies, Maria A. Quintero, Amber Delmas, Sophia Diaz, Catherine D. Martinez, Thomas Venables, Adrian Reich, Gogce Crynen, Amar R. Deshpande, David H. Kerman, Oriana M. Damas, Irina Fernandez, Ana M. Santander, Judith Pignac-Kobinger, Juan F. Burgueno, Mark S. Sundrud
Summary: Vedolizumab (VDZ) is effective in the treatment of inflammatory bowel disease (IBD) by inhibiting lymphocyte extravasation into intestinal mucosae. Changes in T regulatory cells in the periphery and mucosa have the greatest relationship to VDZ response.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Mona Rezapour, Maria Alejandra Quintero, Nidah S. Khakoo, Daniel A. Sussman, Jodie A. Barkin, Jennifer Clarke, Tanya Varma, Amar R. Deshpande, David H. Kerman, Oriana Damas, Maria T. Abreu
CROHNS & COLITIS 360
(2019)